Diabetes & Endocrinologycardio-kidney-metabolic diseasesemaglutide
Pooled Analysis of SELECT, FLOW, and SOUL Links Semaglutide to Reduced Kidney Outcomes
By MedXY|Aug 8, 2026
A prespecified pooled analysis of three phase 3 trials including 30,787 participants found semaglutide reduced major kidney outcomes versus placebo, with a 16% relative risk reduction in the primary composite and a favourable safety profile across cardio-kidney-metabolic disease.